Bio-Rad Labs (BIO) Tops Q3 EPS by 85c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts BIO Hot Sheet
Price: $374.91 --0%
Revenue Growth %: -0.5%
Financial Fact:
Net income attributable to Bio-Rad: 18.01M
Today's EPS Names:
ATS, SICP, FTCO, More
Revenue Growth %: -0.5%
Financial Fact:
Net income attributable to Bio-Rad: 18.01M
Today's EPS Names:
ATS, SICP, FTCO, More
Join SI Premium – FREE
Bio-Rad Labs (NYSE: BIO) reported Q3 EPS of $2.01, $0.85 better than the analyst estimate of $1.16. Revenue for the quarter came in at $649.7 million versus the consensus estimate of $628.18 million.
For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
- Nucor (NUE) PT Raised to $301 at KeyBanc
- Truist Securities Reiterates Buy Rating on Curbline Properties Corp (CURB)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
